Akebia Therapeutics' anemia treatment fails to meet safety goal in late-stage study
-Akebia Therapeutics Inc said on Thursday its experimental drug to treat anemia in patients with chronic kidney disease failed to meet the main goal on safety in a late-stage trial.
(Reuters) – Akebia Therapeutics Inc said on Thursday its experimental drug to treat anemia in patients with chronic kidney disease failed to meet the main goal on safety in a late-stage trial.
However, the company said its treatment, vadadustat, achieved the main goal and secondary goal on efficacy in each of the two studies.
(Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta)
ANA NEWS WIRE Disclaimer:
The African News Agency (ANA) is a news wire service and therefore subscribes to the highest standards of journalism as it relates to accuracy, fairness and impartiality.
ANA strives to provide accurate, well sourced and reliable information across Text, Images and Video. Where errors do appear, ANA will seek to correct these timeously and transparently.
The ANA platform also contains news and information from third party sources. ANA has sought to procure reliable content from trusted news sources but cannot be held responsible for the accuracy and opinions provided by such sources on the ANA platform or linked sites.
The content provided for on the ANA News Wire platform, both through the ANA news operation and via its third party sources, are for the sole use of authorised subscribers and partners. Unauthorised access to and usage of ANA content will be subject to legal steps. ANA reserves its rights in this regard.
ANA makes every effort to ensure that the website is up and running smoothly at all times, however ANA does not take responsibility for, and will not be held liable for times when the website is temporarily unavailable due to technical issues that are beyond our control.